REPORTS

Let’s Pullulate and Expand Your Business

Vitamin K Antagonists (VKA) Market - Global Professional Analysis and Forecast to 2026

Jan 15, 2020  |  199 PAGES  |  REPORT CODE: CMM261559
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The worldwide Vitamin K Antagonists (VKA) market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 3.4% during the forecast period.

This report presents the market size and development trends by detailing the Vitamin K Antagonists (VKA) market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Vitamin K Antagonists (VKA) market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Vitamin K Antagonists (VKA) industry and will help you to build a panoramic view of the industrial development.

Vitamin K Antagonists (VKA) Market, By Type:

  • Oral Vitamin K Antagonists

  • Injection Vitamin K Antagonists

Vitamin K Antagonists (VKA) Market, By Application:

  • VTE

  • ACS/MI

  • AF

  • Others

Some of the leading players are as follows:

  • The Medicines Company

  • Johnson & Johnson

  • Lilly

  • Sanofi

  • Aspen

  • Pfizer

  • Bristol-Myers Squibb

  • Bayer

  • Otsuka

  • Boehringer Ingelheim

  • AstraZeneca

  • Daiichi Sankyo

  • Genentech (Roche)

Geographically, Major regions are analyzed in details are as follows:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Table of Contents

1 Methodology and Scope

  • 1.1 Market Segmentation & Scope

    • 1.1.1 Technology Type

    • 1.1.2 Product

    • 1.1.3 Application

    • 1.1.4 Regional scope

    • 1.1.5 Estimates and forecast timeline

  • 1.2 Research Methodology

  • 1.3 Information Procurement

    • 1.3.1 Purchased database

    • 1.3.2 Internal database

    • 1.3.3 Secondary sources

    • 1.3.4 Primary research

    • 1.3.5 Details of primary research

  • 1.4 Information or Data Analysis

    • 1.4.1 Data analysis models

  • 1.5 Market Formulation & Validation

  • 1.6 Model Details

    • 1.6.1 Commodity flow analysis

    • 1.6.2 Volume price analysis

  • 1.7 List of Secondary Sources

  • 1.8 List of Abbreviations

2 Executive Summary

  • 2.1 Market Outlook

  • 2.2 Segment Outlook

3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook

  • 3.1.1 Parent market outlook

    • 3.1.2 Ancillary market outlook

  • 3.2 Market Segmentation

    • 3.2.1 Analysis

  • 3.3 Market Dynamics

    • 3.3.1 Market driver analysis

    • 3.3.2 Market restraint analysis

    • 3.3.3 Industry opportunities

  • 3.4 Penetration & Growth Prospect Mapping

    • 3.4.1 Penetration & growth prospect mapping analysis

  • 3.5 Business Environment Analysis Tools

    • 3.5.1 Porter's five forces analysis

    • 3.5.2 PESTLE analysis

    • 3.5.3 Major deals & strategic alliances analysis

4 Vitamin K Antagonists (VKA) Market: Technology Type Analysis

  • 4.1 Vitamin K Antagonists (VKA) Technology Type Market Share Analysis, 2018 & 2026

  • 4.2 Vitamin K Antagonists (VKA) Technology Type Market: Segment Dashboard

  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

    • 4.3.1 Oral Vitamin K Antagonists

    • 4.3.2 Injection Vitamin K Antagonists

5 Vitamin K Antagonists (VKA) Market: Product Analysis

  • 5.1 Vitamin K Antagonists (VKA) Product Market Share Analysis, 2018 & 2026

  • 5.2 Vitamin K Antagonists (VKA) Product Market: Segment Dashboard

  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 Vitamin K Antagonists (VKA) Market: Application Analysis

  • 6.1 Vitamin K Antagonists (VKA) Application Market Share Analysis, 2018 & 2026

  • 6.2 Vitamin K Antagonists (VKA) Application Market: Segment Dashboard

  • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

    • 6.3.1 VTE

    • 6.3.2 ACS/MI

    • 6.3.3 AF

    • 6.3.4 Others

7 Vitamin K Antagonists (VKA) Market: Regional Analysis

  • 7.1 Vitamin K Antagonists (VKA) Regional Market Share Analysis, 2018 & 2026

  • 7.2 Vitamin K Antagonists (VKA) Regional Market: Segment Dashboard

  • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

  • 7.4 List of Players at Regional Level

    • 7.4.1 North America

    • 7.4.2 Europe

    • 7.4.3 Asia Pacific

  • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

    • 7.5.1 North America

    • 7.5.2 Europe

    • 7.5.3 Asia Pacific

    • 7.5.4 Latin America

    • 7.5.5 MEA

  • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

    • 7.6.1 North America

    • 7.6.2 Europe

    • 7.6.3 Asia Pacific

    • 7.6.4 Latin America

    • 7.6.5 Middle East & Africa

8 Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

  • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

  • 8.3 Vendor Landscape

    • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

  • 9.1 The Medicines Company

    • 9.1.1 The Medicines Company Company overview

    • 9.1.2 Financial performance

    • 9.1.3 Product benchmarking

    • 9.1.4 Strategic initiatives

    • 9.1.5 SWOT analysis

  • 9.2 Johnson & Johnson

    • 9.2.1 Johnson & Johnson Company overview

    • 9.2.2 Financial performance

    • 9.2.3 Product benchmarking

    • 9.2.4 Strategic initiatives

    • 9.2.5 SWOT analysis

  • 9.3 Lilly

    • 9.3.1 Lilly Company overview

    • 9.3.2 Financial performance

    • 9.3.3 Product benchmarking

    • 9.3.4 Strategic initiatives

    • 9.3.5 SWOT analysis

  • 9.4 Sanofi

    • 9.4.1 Sanofi Company overview

    • 9.4.2 Financial performance

    • 9.4.3 Product benchmarking

    • 9.4.4 Strategic initiatives

    • 9.4.5 SWOT analysis

  • 9.5 Aspen

    • 9.5.1 Aspen Company overview

    • 9.5.2 Financial performance

    • 9.5.3 Product benchmarking

    • 9.5.4 Strategic initiatives

    • 9.5.5 SWOT analysis

  • 9.6 Pfizer

    • 9.6.1 Pfizer Company overview

    • 9.6.2 Financial performance

    • 9.6.3 Product benchmarking

    • 9.6.4 Strategic initiatives

    • 9.6.5 SWOT analysis

  • 9.7 Bristol-Myers Squibb

    • 9.7.1 Bristol-Myers Squibb Company overview

    • 9.7.2 Financial performance

    • 9.7.3 Product benchmarking

    • 9.7.4 Strategic initiatives

    • 9.7.5 SWOT analysis

  • 9.8 Bayer

    • 9.8.1 Bayer Company overview

    • 9.8.2 Financial performance

    • 9.8.3 Product benchmarking

    • 9.8.4 Strategic initiatives

    • 9.8.5 SWOT analysis

  • 9.9 Otsuka

    • 9.9.1 Otsuka Company overview

    • 9.9.2 Financial performance

    • 9.9.3 Product benchmarking

    • 9.9.4 Strategic initiatives

    • 9.9.5 SWOT analysis

  • 9.10 Boehringer Ingelheim

    • 9.10.1 Boehringer Ingelheim Company overview

    • 9.10.2 Financial performance

    • 9.10.3 Product benchmarking

    • 9.10.4 Strategic initiatives

    • 9.10.5 SWOT analysis

  • 9.11 AstraZeneca

    • 9.11.1 AstraZeneca Company overview

    • 9.11.2 Financial performance

    • 9.11.3 Product benchmarking

    • 9.11.4 Strategic initiatives

    • 9.11.5 SWOT analysis

  • 9.12 Daiichi Sankyo

    • 9.12.1 Daiichi Sankyo Company overview

    • 9.12.2 Financial performance

    • 9.12.3 Product benchmarking

    • 9.12.4 Strategic initiatives

    • 9.12.5 SWOT analysis

  • 9.13 Genentech (Roche)

    • 9.13.1 Genentech (Roche) Company overview

    • 9.13.2 Financial performance

    • 9.13.3 Product benchmarking

    • 9.13.4 Strategic initiatives

    • 9.13.5 SWOT analysis

 

The List of Tables and Figures (Totals 90 Figures and 142 Tables)

  • Figure Oral Vitamin K Antagonists Vitamin K Antagonists (VKA) market, 2015 - 2026 (USD Million)

  • Figure Injection Vitamin K Antagonists Vitamin K Antagonists (VKA) market, 2015 - 2026 (USD Million)

  • Figure VTE market, 2015 - 2026 (USD Million)

  • Figure ACS/MI market, 2015 - 2026 (USD Million)

  • Figure AF market, 2015 - 2026 (USD Million)

  • Figure Others market, 2015 - 2026 (USD Million)

  • Table List of players in North America

  • Table List of players in Europe

  • Table List of players in Asia Pacific

  • Table SWOT analysis

  • Table North America Vitamin K Antagonists (VKA) market, by country, 2015 - 2026 (USD Million)

  • Table North America Vitamin K Antagonists (VKA) market, by type, 2015 - 2026 (USD Million)

  • Table North America Vitamin K Antagonists (VKA) market, by product, 2015 - 2026 (USD Million)

  • Table North America Vitamin K Antagonists (VKA) market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.S. Vitamin K Antagonists (VKA) market, by type, 2015 - 2026 (USD Million)

  • Table U.S. Vitamin K Antagonists (VKA) market, by product, 2015 - 2026 (USD Million)

  • Table U.S. Vitamin K Antagonists (VKA) market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Canada Vitamin K Antagonists (VKA) market, by type, 2015 - 2026 (USD Million)

  • Table Canada Vitamin K Antagonists (VKA) market, by product, 2015 - 2026 (USD Million)

  • Table Canada Vitamin K Antagonists (VKA) market, by application, 2015 - 2026 (USD Million)

  • Table Europe Vitamin K Antagonists (VKA) market, by country, 2015 - 2026 (USD Million)

  • Table Europe Vitamin K Antagonists (VKA) market, by type, 2015 - 2026 (USD Million)

  • Table Europe Vitamin K Antagonists (VKA) market, by product, 2015 - 2026 (USD Million)

  • Table Europe Vitamin K Antagonists (VKA) market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.K. Vitamin K Antagonists (VKA) market, by type, 2015 - 2026 (USD Million)

  • Table U.K. Vitamin K Antagonists (VKA) market, by product, 2015 - 2026 (USD Million)

  • Table U.K. Vitamin K Antagonists (VKA) market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Germany Vitamin K Antagonists (VKA) market, by type, 2015 - 2026 (USD Million)

  • Table Germany Vitamin K Antagonists (VKA) market, by product, 2015 - 2026 (USD Million)

  • Table Germany Vitamin K Antagonists (VKA) market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table France Vitamin K Antagonists (VKA) market, by type, 2015 - 2026 (USD Million)

  • Table France Vitamin K Antagonists (VKA) market, by product, 2015 - 2026 (USD Million)

  • Table France Vitamin K Antagonists (VKA) market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Italy Vitamin K Antagonists (VKA) market, by type, 2015 - 2026 (USD Million)

  • Table Italy Vitamin K Antagonists (VKA) market, by product, 2015 - 2026 (USD Million)

  • Table Italy Vitamin K Antagonists (VKA) market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Spain Vitamin K Antagonists (VKA) market, by type, 2015 - 2026 (USD Million)

  • Table Spain Vitamin K Antagonists (VKA) market, by product, 2015 - 2026 (USD Million)

  • Table Spain Vitamin K Antagonists (VKA) market, by application, 2015 - 2026 (USD Million)

  • Table Asia Pacific Vitamin K Antagonists (VKA) market, by country, 2015 - 2026 (USD Million)

  • Table Asia Pacific Vitamin K Antagonists (VKA) market, by type, 2015 - 2026 (USD Million)

  • Table Asia Pacific Vitamin K Antagonists (VKA) market, by product, 2015 - 2026 (USD Million)

  • Table Asia Pacific Vitamin K Antagonists (VKA) market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table China Vitamin K Antagonists (VKA) market, by type, 2015 - 2026 (USD Million)

  • Table China Vitamin K Antagonists (VKA) market, by product, 2015 - 2026 (USD Million)

  • Table China Vitamin K Antagonists (VKA) market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Japan Vitamin K Antagonists (VKA) market, by type, 2015 - 2026 (USD Million)

  • Table Japan Vitamin K Antagonists (VKA) market, by product, 2015 - 2026 (USD Million)

  • Table Japan Vitamin K Antagonists (VKA) market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table India Vitamin K Antagonists (VKA) market, by type, 2015 - 2026 (USD Million)

  • Table India Vitamin K Antagonists (VKA) market, by product, 2015 - 2026 (USD Million)

  • Table India Vitamin K Antagonists (VKA) market, by application, 2015 - 2026 (USD Million)

  • Table Latin America Vitamin K Antagonists (VKA) market, by country, 2015 - 2026 (USD Million)

  • Table Latin America Vitamin K Antagonists (VKA) market, by type, 2015 - 2026 (USD Million)

  • Table Latin America Vitamin K Antagonists (VKA) market, by product, 2015 - 2026 (USD Million)

  • Table Latin America Vitamin K Antagonists (VKA) market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Brazil Vitamin K Antagonists (VKA) market, by type, 2015 - 2026 (USD Million)

  • Table Brazil Vitamin K Antagonists (VKA) market, by product, 2015 - 2026 (USD Million)

  • Table Brazil Vitamin K Antagonists (VKA) market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Mexico Vitamin K Antagonists (VKA) market, by type, 2015 - 2026 (USD Million)

  • Table Mexico Vitamin K Antagonists (VKA) market, by product, 2015 - 2026 (USD Million)

  • Table Mexico Vitamin K Antagonists (VKA) market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Argentina Vitamin K Antagonists (VKA) market, by type, 2015 - 2026 (USD Million)

  • Table Argentina Vitamin K Antagonists (VKA) market, by product, 2015 - 2026 (USD Million)

  • Table Argentina Vitamin K Antagonists (VKA) market, by application, 2015 - 2026 (USD Million)

  • Table MEA Vitamin K Antagonists (VKA) market, by country, 2015 - 2026 (USD Million)

  • Table MEA Vitamin K Antagonists (VKA) market, by type, 2015 - 2026 (USD Million)

  • Table MEA Vitamin K Antagonists (VKA) market, by product, 2015 - 2026 (USD Million)

  • Table MEA Vitamin K Antagonists (VKA) market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table South Africa Vitamin K Antagonists (VKA) market, by type, 2015 - 2026 (USD Million)

  • Table South Africa Vitamin K Antagonists (VKA) market, by product, 2015 - 2026 (USD Million)

  • Table South Africa Vitamin K Antagonists (VKA) market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Nigeria Vitamin K Antagonists (VKA) market, by type, 2015 - 2026 (USD Million)

  • Table Nigeria Vitamin K Antagonists (VKA) market, by product, 2015 - 2026 (USD Million)

  • Table Nigeria Vitamin K Antagonists (VKA) market, by application, 2015 - 2026 (USD Million)

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Company market position analysis

  • Table Company Profiles

  • Table The Medicines Company Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Johnson & Johnson Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Lilly Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Sanofi Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Aspen Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Pfizer Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Bristol-Myers Squibb Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Bayer Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Otsuka Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Boehringer Ingelheim Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table AstraZeneca Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Daiichi Sankyo Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Genentech (Roche) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

Report Purchase

reports
$3850
$7700
BUY NOWClick MeBUY NOW
top